Metastatic breast cancer is complex, requiring holistic care and ongoing treatment, with varying prognosis depending on ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

When there are higher than normal amounts of HER2 on breast cancer cells, the cancer is called HER2 positive. And these cancer cells can grow more rapidly than other breast cancers. HER2 positive ...

Antibody treatment which activates the patient's own immune system against cancer, known as immunotherapy, is increasingly ...

The peritoneal cavity, which contains the abdominal organs, is a less common but still potential site for breast cancer to ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Less than two months ago, 52-year-old Oklahoma State Representative Melissa Provenzano underwent a mastectomy for stage one ...

When you have HER2-negative advanced (metastatic) breast cancer, treatment usually focuses on managing your disease, not curing the cancer. The goal is to help you live longer and have a better ...